文献速递生殖医学

利用高通量筛选进行男性生育力低下药物发现:解决未解难题的新方法

Drug discovery for male subfertility using high-throughput screening: a new approach to an unsolved problem.
PubMed 文献 · Hum Reprod · 2017-01-01

本研究开发并验证了以精子内钙离子浓度作为 motility 替代指标的高通量筛选 assay,对 3242 种离子通道库配体进行筛选,384 种(11.8%)显著增加钙荧光;48 种命中化合物浓度依赖性增加钙离子,其中两种化合物在健康供精者和接受生育治疗患者精子穿透试验中均显著改善功能性 motility,机制主要涉及 CatSper 通道。

要点

  • 高通量筛选可高效鉴定增加人精子内钙离子并功能性改善 motility 的新化合物。
  • 3242 种离子通道库配体中 384 种(11.8%)显著增加钙荧光,48 种为命中化合物。
  • 两种命中化合物在供精者和患者精子穿透试验中均显著改善功能性 motility。

核心结论

  • 高通量筛选能够稳健、高效地鉴定增加人精子内钙离子并功能性改善 motility 的新化合物,作者提议将其作为构建和转化男性不育迫切所需药物发现的基石。

研究设计与样本

  • 研究于 2012 年 1 月至 2016 年 11 月从健康志愿研究供精者和在医院辅助生殖技术诊所接受 IVF/ICSI 的生育力低下患者获取精子。
  • 开发并验证了以精子内钙离子([Ca2+]i)作为 motility 替代指标的高通量筛选 assay,使用 Flexstation 微孔板阅读器(384 孔平台)检测钙荧光,并与孕酮诱发的反应比较。
  • 对 Dundee 大学药物发现单位组装的离子通道聚焦库进行单点药物筛选(10 μM),命中化合物用标准 10 点半对数浓度曲线复筛以确保效力,并用液相色谱和质谱检测纯度和完整性。
  • 命中化合物按构效关系分组,选取 5 种代表性化合物用计算机辅助精子评估、精子穿透试验和全细胞膜片钳进一步研究其对精子的直接效应。

主要发现

  • 筛选的 3242 种离子通道库配体中,384 种化合物(11.8%)引起钙荧光统计学显著增加,超过基线中位绝对偏差 3 倍以上。
  • 初筛中 74 种引起荧光增加≥50% 的化合物被复筛并进一步评估,最终 48 种命中化合物产生浓度依赖性 [Ca2+]i 增加。
  • 精子穿透研究证实体外暴露于两种命中化合物(A 和 B)使健康志愿供精者精子功能性 motility 显著改善(A:1 cm 穿透指数 2.54,2 cm 穿透指数 2.49;P < 0.005;B:1 cm 穿透指数 2.1,2 cm 穿透指数 2.6;P < 0.005)。
  • 在接受生育治疗的患者样本中也观察到显著改善(A:1 cm 穿透指数 2.4;P = 0.009,2 cm 穿透指数 3.6;P = 0.02;B:1 cm 穿透指数 2.2;P = 0.0004,2 cm 穿透指数 3.6;P = 0.002)。
  • 该效应主要源于直接或间接的 CatSper 通道作用,得到单个精子电生理研究的支持。

临床怎么用

  • 作者认为高通量筛选可作为构建和转化男性不育药物发现的基石。

局限性

  • 原文指出 [Ca2+]i 的增加和通量是精子 motility 及功能(包括顶体反应)调控的基础,使用钙信号作为精子 motility 的替代指标是本研究的潜在局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can pharma drug discovery approaches be utilized to transform investigation into novel therapeutics for male infertility? SUMMARY ANSWER: High-throughput screening (HTS) is a viable approach to much-needed drug discovery for male factor infertility. WHAT IS KNOWN ALREADY: There is both huge demand and a genuine clinical need for new treatment options for infertile men. However, the time, effort and resources required for drug discovery are currently exorbitant, due to the unique challenges of the cellular, physical and functional properties of human spermatozoa and a lack of appropriate assay platform. STUDY DESIGN, SIZE, DURATION: Spermatozoa were obtained from healthy volunteer research donors and subfertile patients undergoing IVF/ICSI at a hospital-assisted reproductive techniques clinic between January 2012 and November 2016. PARTICIPANTS/MATERIALS, SETTING, METHODS: A HTS assay was developed and validated using intracellular calcium ([Ca2+]i) as a surrogate for motility in human spermatozoa. Calcium fluorescence was detected using a Flexstation microplate reader (384-well platform) and compared with responses evoked by progesterone, a compound known to modify a number of biologically relevant behaviours in human spermatozoa. Hit compounds identified following single point drug screen (10 μM) of an ion channel-focussed library assembled by the University of Dundee Drug Discovery Unit were rescreened to ensure potency using standard 10 point half-logarithm concentration curves, and tested for purity and integrity using liquid chromatography and mass spectrometry. Hit compounds were grouped by structure activity relationships and five representative compounds then further investigated for direct effects on spermatozoa, using computer-assisted sperm assessment, sperm penetration assay and whole-cell patch clamping. MAIN RESULTS AND THE ROLE OF CHANCE: Of the 3242 ion channel library ligands screened, 384 compounds (11.8%) elicited a statistically significant increase in calcium fluorescence, with greater than 3× median absolute deviation above the baseline. Seventy-four compounds eliciting ≥50% increase in fluorescence in the primary screen were rescreened and evaluated further, resulting in 48 hit compounds that produced a concentration-dependent increase in [Ca2+]i. Sperm penetration studies confirmed in vitro exposure to two hit compounds (A and B) resulted in significant improvement in functional motility in spermatozoa from healthy volunteer donors (A: 1 cm penetration index 2.54, 2 cm penetration index 2.49; P < 0.005 and B: 1 cm penetration index 2.1, 2 cm penetration index 2.6; P < 0.005), but crucially, also in patient samples from those undergoing fertility treatment (A: 1 cm penetration index 2.4; P = 0.009, 2 cm penetration index 3.6; P = 0.02 and B: 1 cm penetration index 2.2; P = 0.0004, 2 cm penetration index 3.6; P = 0.002). This was primarily as a result of direct or indirect CatSper channel action, supported by evidence from electrophysiology studies of individual sperm. LIMITATIONS, REASONS FOR CAUTION: Increase and fluxes in [Ca2+]i are fundamental to the regulation of sperm motility and function, including acrosome reaction. The use of calcium signalling as a surrogate for sperm motility is acknowledged as a potential limitation in this study. WIDER IMPLICATIONS OF THE FINDINGS: We conclude that HTS can robustly, efficiently, identify novel compounds that increase [Ca2+]i in human spermatozoa and functionally modify motility, and propose its use as a cornerstone to build and transform much-needed drug discovery for male infertility. STUDY FUNDING/COMPETING INTEREST(S): The majority of the data were obtained using funding from TENOVUS Scotland and Chief Scientist Office NRS Fellowship. Additional funding was provided by NHS Tayside, MRC project grants (MR/K013343/1, MR/012492/1) and University of Abertay. The authors declare that there is no conflict of interest. TRAIL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Martins da Silva SJ, Brown SG, Sutton K, et al. Drug discovery for male subfertility using high-throughput screening: a new approach to an unsolved problem. Hum Reprod. 2017. PMID: 28333338. doi:10.1093/humrep/dex055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。